Kaj Blennow

Research interests

Publications

• Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

  JAMA Neurology · 2024 · https://doi.org/10.1001/jamaneurol.2023.5319

• Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease

  Brain · 2022 · https://doi.org/10.1093/brain/awac333

• The Amyloid-β Pathway in Alzheimer’s Disease

  Molecular Psychiatry · 2021 · https://doi.org/10.1038/s41380-021-01249-0

• A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease

  Nature Genetics · 2021 · 10.1038/s41588-021-00921-z

• Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease

  JAMA Neurology · 2021 · https://doi.org/10.1001/jamaneurol.2021.3180

• Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology

  Acta Neuropathologica · 2021 · https://doi.org/10.1007/s00401-021-02275-6

• Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

  The Lancet Neurology · 2020 · 10.1016/s1474-4422(20)30071-5

• Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

  JAMA · 2020 · 10.1001/jama.2020.12134

• Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

  Nature Medicine · 2020 · 10.1038/s41591-020-0755-1

• Neurofilament light chain as a biomarker in neurological disorders

  Journal of Neurology Neurosurgery & Psychiatry · 2019 · 10.1136/jnnp-2018-320106

• Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology

  JAMA Neurology · 2019 · 10.1001/jamaneurol.2019.1534

• Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic

  Nature Reviews Neurology · 2018 · 10.1038/s41582-018-0079-7

• NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

  Alzheimer s & Dementia · 2018 · https://doi.org/10.1016/j.jalz.2018.02.018

• Neurofilaments as biomarkers in neurological disorders

  Nature Reviews Neurology · 2018 · 10.1038/s41582-018-0058-z

• Gut microbiome alterations in Alzheimer’s disease

  Scientific Reports · 2017 · 10.1038/s41598-017-13601-y

• Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis

  Annals of Neurology · 2017 · 10.1002/ana.24954

• CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

  The Lancet Neurology · 2016 · 10.1016/s1474-4422(16)00070-3

• A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

  Neurology · 2016 · 10.1212/wnl.0000000000002923

• Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

  Alzheimer s & Dementia · 2016 · 10.1016/j.jalz.2016.02.002

• Alzheimer's disease

  The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(15)01124-1

• Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

  JAMA · 2015 · 10.1001/jama.2015.4668

• Clearance systems in the brain—implications for Alzheimer disease

  Nature Reviews Neurology · 2015 · 10.1038/nrneurol.2015.119

• Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

  The Lancet Neurology · 2014 · https://doi.org/10.1016/s1474-4422(14)70090-0

• Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1304839

• 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

  The Lancet Neurology · 2010 · 10.1016/s1474-4422(10)70043-0

• Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

  Nature Reviews Neurology · 2010 · 10.1038/nrneurol.2010.4

• Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

  Annals of Neurology · 2009 · 10.1002/ana.21610

• Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

  Nature Medicine · 2007 · 10.1038/nm1653

• Alzheimer's disease

  The Lancet · 2006 · https://doi.org/10.1016/s0140-6736(06)69113-7

• Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

  The Lancet Neurology · 2006 · 10.1016/s1474-4422(06)70355-6

• Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment

  Journal of Internal Medicine · 2004 · https://doi.org/10.1111/j.1365-2796.2004.01380.x

• CSF markers for incipient Alzheimer's disease

  The Lancet Neurology · 2003 · 10.1016/s1474-4422(03)00530-1

Current projects

No projects listed.